Oxford University Clinical Research Unit, Hospital for Tropical Diseases, 190 Ben Ham Tu, District 5, Ho Chi Minh City, Vietnam.
Antimicrob Agents Chemother. 2009 Nov;53(11):4835-9. doi: 10.1128/AAC.00541-09. Epub 2009 Aug 31.
Consecutive fluoroquinolone (FQ)-resistant isolates (n = 109) identified at the Pham Ngoc Thach Hospital for Tuberculosis, Ho Chi Minh City, Vietnam, were sequenced in the quinolone resistance-determining regions of the gyrA and gyrB genes and typed by large sequence polymorphism typing and spoligotyping to identify the Beijing genotype of Mycobacterium tuberculosis. Beijing genotype prevalence was compared with 109 consecutive isolates from newly presenting patients with pulmonary tuberculosis from the hospital outpatient department. Overall, 82.6% (n = 90/109) of isolates had mutations in gyrAB. Nine novel mutations were identified in gyrB (S486F, N538T, T539P, D500A, D500H, D500N, G509A, E540V, and E540D). The influence of these novel gyrB mutations on FQ resistance is not proven. The Beijing genotype was significantly associated with FQ resistance (odds ratio [OR], 2.39 [95% confidence interval {CI}, 1.34 to 4.25]; P = 0.003). Furthermore, Beijing genotype FQ-resistant isolates were significantly more likely than FQ-resistant isolates of other genotypes to have gyrA mutations (OR, 7.75 [95% CI, 2.84 to 21.15]; P = 0.0001) and high-level (>8 microg/ml) FQ resistance (OR, 11.0 [95% CI, 2.6 to 47.0]; P = 0.001). The underlying mechanism of the association of the Beijing genotype with high-level FQ resistance in this setting remains to be determined. The association of the Beijing genotype with relatively high-level FQ resistance conferred by specific gyrA mutations reported here is of grave concern given the epidemic spread of the Beijing genotype and the current hopes for shorter first-line treatment regimens based on FQs.
在越南胡志明市范玉石结核病医院,连续分离出的氟喹诺酮(FQ)耐药株(n=109)在gyrA 和 gyrB 基因的喹诺酮耐药决定区进行测序,并通过大序列多态性分型和 spoligotyping 进行结核分枝杆菌北京基因型鉴定。比较了北京基因型的流行率与医院门诊部新出现的肺结核患者的 109 例连续分离株。总体而言,82.6%(n=90/109)的分离株在 gyrAB 中存在突变。在 gyrB 中发现了 9 种新的突变(S486F、N538T、T539P、D500A、D500H、D500N、G509A、E540V 和 E540D)。这些新的 gyrB 突变对 FQ 耐药性的影响尚未得到证实。北京基因型与 FQ 耐药显著相关(比值比[OR],2.39[95%置信区间{CI},1.34 至 4.25];P=0.003)。此外,与其他基因型的 FQ 耐药分离株相比,北京基因型 FQ 耐药分离株更有可能发生 gyrA 突变(OR,7.75[95%CI,2.84 至 21.15];P=0.0001)和高水平(>8μg/ml)FQ 耐药(OR,11.0[95%CI,2.6 至 47.0];P=0.001)。在这种情况下,北京基因型与高水平 FQ 耐药相关的潜在机制仍有待确定。鉴于北京基因型的流行传播以及当前基于 FQ 的更短一线治疗方案的希望,北京基因型与报道的特定 gyrA 突变引起的相对高水平 FQ 耐药相关的关联令人严重关切。